{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T02:09:16Z","timestamp":1791425356006,"version":"4.3.3"},"reference-count":51,"publisher":"American Society of Hematology","issue":"8","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2012,8,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Immunotherapy with therapeutic idiotype vaccines offers promise for treatment of B-cell malignancies. However, identification of novel immunogenic lymphoma-associated antigens that are universally expressed is necessary to overcome the barriers of patient-specific idiotype vaccines. Here, we determined whether T-cell leukemia\/lymphoma 1 (TCL1) oncoprotein encoded by the TCL1 gene could be a target for immunotherapy of B-cell malignancies. We show that TCL1 mRNA and protein are selectively expressed in normal B cells but markedly hyperexpressed in multiple human B-cell lymphomas, including follicular lymphoma, chronic lymphocytic leukemia, mantle cell lymphoma, diffuse large B-cell lymphoma, and splenic marginal zone B-cell lymphoma. We demonstrated that TCL1-specific CD8+ T cells can be generated from HLA-A*0201 (HLA-A2)+ normal donors and identified TCL171-78 (LLPIMWQL) as the minimal epitope recognized by these T cells. More importantly, TCL171-78 peptide-specific T cells were present in the peripheral blood and tumor-infiltrating lymphocytes of lymphoma patients, could be expanded in vitro, and lysed autologous tumor cells but not normal B cells in an HLA-A2\u2013restricted manner. Our results suggest that TCL1 is naturally processed and presented on the surface of lymphoma cells for recognition by cytotoxic T cells and can serve as a novel target for development of immunotherapeutic strategies against common B-cell lymphomas.<\/jats:p>","DOI":"10.1182\/blood-2011-09-382838","type":"journal-article","created":{"date-parts":[[2012,5,30]],"date-time":"2012-05-30T02:09:16Z","timestamp":1338343756000},"page":"1613-1623","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":33,"title":["TCL1: a shared tumor-associated antigen for immunotherapy against B-cell lymphomas"],"prefix":"10.1182","volume":"120","author":[{"given":"Jinsheng","family":"Weng","sequence":"first","affiliation":[{"name":"Department of Lymphoma and Myeloma, Division of Cancer Medicine, and"},{"name":"Center for Cancer Immunology Research, The University of Texas MD Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seema","family":"Rawal","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma, Division of Cancer Medicine, and"},{"name":"Center for Cancer Immunology Research, The University of Texas MD Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuliang","family":"Chu","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma, Division of Cancer Medicine, and"},{"name":"Center for Cancer Immunology Research, The University of Texas MD Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun Jun","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma, Division of Cancer Medicine, and"},{"name":"Center for Cancer Immunology Research, The University of Texas MD Anderson Cancer Center, Houston, TX;"},{"name":"The University of Texas Graduate School of Biomedical Sciences, Houston, TX; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh","family":"Sharma","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma, Division of Cancer Medicine, and"},{"name":"Center for Cancer Immunology Research, The University of Texas MD Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Delgado","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma, Division of Cancer Medicine, and"},{"name":"Center for Cancer Immunology Research, The University of Texas MD Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Fayad","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma, Division of Cancer Medicine, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Fanale","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma, Division of Cancer Medicine, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Romaguera","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma, Division of Cancer Medicine, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amber","family":"Luong","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology-Head and Neck Surgery, The University of Texas Medical School at Houston, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry W.","family":"Kwak","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma, Division of Cancer Medicine, and"},{"name":"Center for Cancer Immunology Research, The University of Texas MD Anderson Cancer Center, Houston, TX;"},{"name":"The University of Texas Graduate School of Biomedical Sciences, Houston, TX; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sattva S.","family":"Neelapu","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma, Division of Cancer Medicine, and"},{"name":"Center for Cancer Immunology Research, The University of Texas MD Anderson Cancer Center, Houston, TX;"},{"name":"The University of Texas Graduate School of Biomedical Sciences, Houston, TX; and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"4","key":"2019111810221602400_B1","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1182\/blood-2004-08-3175","article-title":"CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma.","volume":"105","author":"Marcus","year":"2005","journal-title":"Blood"},{"issue":"6","key":"2019111810221602400_B2","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1056\/NEJMra0708875","article-title":"Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma.","volume":"359","author":"Cheson","year":"2008","journal-title":"N Engl J Med"},{"issue":"4","key":"2019111810221602400_B3","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.","volume":"346","author":"Coiffier","year":"2002","journal-title":"N Engl J Med"},{"issue":"2","key":"2019111810221602400_B4","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/j.1365-2141.2008.07143.x","article-title":"Developing idiotype vaccines for lymphoma: from preclinical studies to phase III clinical trials.","volume":"142","author":"Park","year":"2008","journal-title":"Br J Haematol"},{"issue":"1","key":"2019111810221602400_B5","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1182\/blood-2008-06-165654","article-title":"Vaccination with autologous tumor-loaded dendritic cells induces clinical and immunologic responses in indolent B-cell lymphoma patients with relapsed and measurable disease: a pilot study.","volume":"113","author":"Di Nicola","year":"2009","journal-title":"Blood"},{"issue":"5","key":"2019111810221602400_B6","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1182\/blood.V99.5.1517","article-title":"Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients.","volume":"99","author":"Timmerman","year":"2002","journal-title":"Blood"},{"issue":"5","key":"2019111810221602400_B7","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1182\/blood-2010-06-292342","article-title":"Upfront immunization with autologous recombinant idiotype Fab fragment without prior cytoreduction in indolent B-cell lymphoma.","volume":"117","author":"Navarrete","year":"2011","journal-title":"Blood"},{"issue":"8","key":"2019111810221602400_B8","doi-asserted-by":"crossref","first-page":"4496","DOI":"10.1158\/0008-5472.CAN-05-4233","article-title":"Phase I trial of a novel intradermal idiotype vaccine in patients with advanced B-cell lymphoma: specific immune responses despite profound immunosuppression.","volume":"66","author":"Bertinetti","year":"2006","journal-title":"Cancer Res"},{"issue":"9","key":"2019111810221602400_B9","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1038\/nm1290","article-title":"Vaccine-induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma.","volume":"11","author":"Neelapu","year":"2005","journal-title":"Nat Med"},{"issue":"10","key":"2019111810221602400_B10","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1038\/13928","article-title":"Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma.","volume":"5","author":"Bendandi","year":"1999","journal-title":"Nat Med"},{"issue":"17","key":"2019111810221602400_B11","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJM199210223271705","article-title":"Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors.","volume":"327","author":"Kwak","year":"1992","journal-title":"N Engl J Med"},{"issue":"20","key":"2019111810221602400_B12","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1200\/JCO.2010.33.3005","article-title":"Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma.","volume":"29","author":"Schuster","year":"2011","journal-title":"J Clin Oncol"},{"issue":"2","key":"2019111810221602400_B13","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/modpathol.2008.148","article-title":"TCL1A expression delineates biological and clinical variability in B-cell lymphoma.","volume":"22","author":"Aggarwal","year":"2009","journal-title":"Mod Pathol"},{"issue":"8","key":"2019111810221602400_B14","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1038\/nrc1672","article-title":"The TCL1 family of oncoproteins: co-activators of transformation.","volume":"5","author":"Teitell","year":"2005","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"2019111810221602400_B15","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/labinvest.3780264","article-title":"TCL1 oncogene expression in B cell subsets from lymphoid hyperplasia and distinct classes of B cell lymphoma.","volume":"81","author":"Said","year":"2001","journal-title":"Lab Invest"},{"issue":"8","key":"2019111810221602400_B16","first-page":"2095","article-title":"Regulation of TCL1 expression in B- and T-cell lymphomas and reactive lymphoid tissues.","volume":"60","author":"Narducci","year":"2000","journal-title":"Cancer Res"},{"issue":"18","key":"2019111810221602400_B17","doi-asserted-by":"crossref","first-page":"11712","DOI":"10.1073\/pnas.182412399","article-title":"TCL1 participates in early embryonic development and is overexpressed in human seminomas.","volume":"99","author":"Narducci","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"24","key":"2019111810221602400_B18","first-page":"5452","article-title":"TCL1 is overexpressed in patients affected by adult T-cell leukemias.","volume":"57","author":"Narducci","year":"1997","journal-title":"Cancer Res"},{"issue":"2","key":"2019111810221602400_B19","doi-asserted-by":"crossref","first-page":"864","DOI":"10.4049\/jimmunol.175.2.864","article-title":"T cell leukemia-1 modulates TCR signal strength and IFN-gamma levels through phosphatidylinositol 3-kinase and protein kinase C pathway activation.","volume":"175","author":"Hoyer","year":"2005","journal-title":"J Immunol"},{"issue":"2","key":"2019111810221602400_B20","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S1097-2765(00)00039-3","article-title":"The protooncogene TCL1 is an Akt kinase coactivator.","volume":"6","author":"Laine","year":"2000","journal-title":"Mol Cell"},{"issue":"7","key":"2019111810221602400_B21","doi-asserted-by":"crossref","first-page":"3885","DOI":"10.1073\/pnas.95.7.3885","article-title":"Deregulated expression of TCL1 causes T cell leukemia in mice.","volume":"95","author":"Virgilio","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"2019111810221602400_B22","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1182\/blood.V92.2.368","article-title":"Transgenic mice for MTCP1 develop T-Cell prolymphocytic leukemia.","volume":"92","author":"Gritti","year":"1998","journal-title":"Blood"},{"issue":"22","key":"2019111810221602400_B23","doi-asserted-by":"crossref","first-page":"14392","DOI":"10.1073\/pnas.212410199","article-title":"Dysregulated TCL1 promotes multiple classes of mature B cell lymphoma.","volume":"99","author":"Hoyer","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2019111810221602400_B24","first-page":"151","article-title":"Identification of TCL1A as an immunohistochemical marker of adverse outcome in diffuse large B-cell lymphomas.","volume":"26","author":"Ramuz","year":"2005","journal-title":"Int J Oncol"},{"issue":"50","key":"2019111810221602400_B25","doi-asserted-by":"crossref","first-page":"19643","DOI":"10.1073\/pnas.0810965105","article-title":"Tcl1 functions as a transcriptional regulator and is directly involved in the pathogenesis of CLL.","volume":"105","author":"Pekarsky","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"21","key":"2019111810221602400_B26","doi-asserted-by":"crossref","first-page":"4675","DOI":"10.1182\/blood-2009-03-208256","article-title":"High TCL1 levels are a marker of B-cell receptor pathway responsiveness and adverse outcome in chronic lymphocytic leukemia.","volume":"114","author":"Herling","year":"2009","journal-title":"Blood"},{"issue":"1-2","key":"2019111810221602400_B27","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jim.2007.09.006","article-title":"A novel strategy for rapid and efficient isolation of human tumor-specific CD4+ and CD8+ T-cell clones.","volume":"331","author":"Lee","year":"2008","journal-title":"J Immunol Methods"},{"key":"2019111810221602400_B28","unstructured":"The Oncomine database.\n          Accessed February 5, 2009\n          \n            http:\/\/www.oncomine.org\/resource"},{"issue":"4","key":"2019111810221602400_B29","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s00262-002-0273-7","article-title":"A simple culture protocol to detect peptide-specific cytotoxic T lymphocyte precursors in the circulation.","volume":"51","author":"Hida","year":"2002","journal-title":"Cancer Immunol Immunother"},{"issue":"7","key":"2019111810221602400_B30","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1097\/PAS.0b013e31802e2201","article-title":"TCL1 in B-cell tumors retains its normal b-cell pattern of regulation and is a marker of differentiation stage.","volume":"31","author":"Herling","year":"2007","journal-title":"Am J Surg Pathol"},{"issue":"6402","key":"2019111810221602400_B31","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1038\/360364a0","article-title":"Different length peptides bind to HLA-Aw68 similarly at their ends but bulge out in the middle.","volume":"360","author":"Guo","year":"1992","journal-title":"Nature"},{"issue":"10","key":"2019111810221602400_B32","doi-asserted-by":"crossref","first-page":"6358","DOI":"10.1074\/jbc.M512263200","article-title":"A long N-terminal-extended Nested Set of Abundant and Antigenic Major Histocompatibility Complex class I natural ligands from HIV envelope protein.","volume":"281","author":"Samino","year":"2006","journal-title":"J Biol Chem"},{"issue":"11","key":"2019111810221602400_B33","doi-asserted-by":"crossref","first-page":"3089","DOI":"10.1002\/1521-4141(200011)30:11<3089::AID-IMMU3089>3.0.CO;2-5","article-title":"Longer peptide can be accommodated in the MHC class I binding site by a protrusion mechanism.","volume":"30","author":"Stryhn","year":"2000","journal-title":"Eur J Immunol"},{"issue":"6498","key":"2019111810221602400_B34","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/371626a0","article-title":"Three-dimensional structure of a peptide extending from one end of a class I MHC binding site.","volume":"371","author":"Collins","year":"1994","journal-title":"Nature"},{"issue":"1","key":"2019111810221602400_B35","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.coi.2007.12.004","article-title":"Coping with loss of perfection in the MHC class I peptide repertoire.","volume":"20","author":"Blanchard","year":"2008","journal-title":"Curr Opin Immunol"},{"key":"2019111810221602400_B36","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1479-5876-3-35","article-title":"T cell avidity and tumor recognition: implications and therapeutic strategies.","volume":"3","author":"McKee","year":"2005","journal-title":"J Transl Med"},{"issue":"5","key":"2019111810221602400_B37","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer.","volume":"363","author":"Kantoff","year":"2010","journal-title":"N Engl J Med"},{"issue":"22","key":"2019111810221602400_B38","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1056\/NEJMoa1012863","article-title":"gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma.","volume":"364","author":"Schwartzentruber","year":"2011","journal-title":"N Engl J Med"},{"issue":"5","key":"2019111810221602400_B39","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1097\/00002371-200409000-00005","article-title":"Characterization of long-term effector-memory T-cell responses in patients with resected high-risk melanoma receiving a melanoma peptide vaccine.","volume":"27","author":"Chiong","year":"2004","journal-title":"J Immunother"},{"issue":"1","key":"2019111810221602400_B40","doi-asserted-by":"crossref","first-page":"350","DOI":"10.4049\/jimmunol.169.1.350","article-title":"Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides.","volume":"169","author":"Zwaveling","year":"2002","journal-title":"J Immunol"},{"issue":"8","key":"2019111810221602400_B41","doi-asserted-by":"crossref","first-page":"5033","DOI":"10.4049\/jimmunol.179.8.5033","article-title":"CD8+ CTL priming by exact peptide epitopes in incomplete Freund's adjuvant induces a vanishing CTL response, whereas long peptides induce sustained CTL reactivity.","volume":"179","author":"Bijker","year":"2007","journal-title":"J Immunol"},{"issue":"5","key":"2019111810221602400_B42","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/nrc2373","article-title":"Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines.","volume":"8","author":"Melief","year":"2008","journal-title":"Nat Rev Cancer"},{"issue":"12","key":"2019111810221602400_B43","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.1182\/blood-2010-08-300376","article-title":"High-avidity cytotoxic T lymphocytes specific for a new PRAME-derived peptide can target leukemic and leukemic-precursor cells.","volume":"117","author":"Quintarelli","year":"2011","journal-title":"Blood"},{"issue":"4","key":"2019111810221602400_B44","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/icb.2008.3","article-title":"The cell biology of cross-presentation and the role of dendritic cell subsets.","volume":"86","author":"Lin","year":"2008","journal-title":"Immunol Cell Biol"},{"issue":"7340","key":"2019111810221602400_B45","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/nature09863","article-title":"Cross-dressed dendritic cells drive memory CD8+ T-cell activation after viral infection.","volume":"471","author":"Wakim","year":"2011","journal-title":"Nature"},{"issue":"6909","key":"2019111810221602400_B46","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/nature01076","article-title":"Direct observation of ligand recognition by T cells.","volume":"419","author":"Irvine","year":"2002","journal-title":"Nature"},{"issue":"2","key":"2019111810221602400_B47","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/S1471-4906(02)00029-7","article-title":"Determinant spreading and tumor responses after peptide-based cancer immunotherapy.","volume":"24","author":"Ribas","year":"2003","journal-title":"Trends Immunol"},{"issue":"4","key":"2019111810221602400_B48","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/CJI.0b013e31824b3b14","article-title":"The Role of antigen cross-presentation from leukemia blasts on immunity to the leukemia-associated antigen PR1.","volume":"35","author":"Alatrash","year":"2012","journal-title":"J Immunother"},{"issue":"6","key":"2019111810221602400_B49","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1136\/adc.74.6.527","article-title":"Treatment of hypogammaglobulinaemia with intravenous immunoglobulin, 1973-93.","volume":"74","author":"Skull","year":"1996","journal-title":"Arch Dis Child"},{"issue":"8","key":"2019111810221602400_B50","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.","volume":"16","author":"McLaughlin","year":"1998","journal-title":"J Clin Oncol"},{"issue":"3","key":"2019111810221602400_B51","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1182\/blood-2004-04-1453","article-title":"Impaired T- and B-cell development in Tcl1-deficient mice.","volume":"105","author":"Kang","year":"2005","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/120\/8\/1613\/1499115\/zh803412001613.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/120\/8\/1613\/1499115\/zh803412001613.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T15:58:33Z","timestamp":1574092713000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/120\/8\/1613\/30814\/TCL1-a-shared-tumorassociated-antigen-for"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8,23]]},"references-count":51,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2012,8,23]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2011-09-382838","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,8,23]]}}}